Trending...
- PebblePad Welcomes Justin Reilly as New CEO to Drive Innovation and Growth
- The World's No.1 Superstar Champions the NO FAKES Act – Secures Global Identity and Cultural Legacy
- HR Tech Awards Program Celebrates 6th Year: Showcases Top Hiring, Talent, and HR Technologies
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time
PHILADELPHIA, June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: https://www.prnewswire.com/news-releases/#finan..." rel="nofollow external noopener">CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company's virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned, without any business being conducted, due to technical difficulties with the third-party hosting site. The meeting will be reconvened at 10:00 a.m. Eastern Time on Friday, June 14, 2024.
Carisma stockholders will be able to attend the virtual annual meeting online, vote their shares electronically and submit questions via the Internet by virtual audio web conference at https://meetnow.global/MAJJ4AY.
More on The PennZone
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.
Media Contact:
Julia Stern
(763) 350-5223
[email protected]
Investors:
Shveta Dighe
Head of Investor Relations
[email protected]
SOURCE Carisma Therapeutics Inc.
PHILADELPHIA, June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: https://www.prnewswire.com/news-releases/#finan..." rel="nofollow external noopener">CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company's virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned, without any business being conducted, due to technical difficulties with the third-party hosting site. The meeting will be reconvened at 10:00 a.m. Eastern Time on Friday, June 14, 2024.
Carisma stockholders will be able to attend the virtual annual meeting online, vote their shares electronically and submit questions via the Internet by virtual audio web conference at https://meetnow.global/MAJJ4AY.
More on The PennZone
- Michael Joseph's A Dollar for Fifty Cents Hits #1 on Amazon's New Releases in Bonds Investing
- "May the Fourth Be With You" Epic Star Wars Day Run/Walk in Alexandria, Va
- Museum Hack Presents Hacked Gala: A Rebellious Night of Art, Fashion, and Change at the Met
- Palladium Energy and Arava Power Company Announce the Sale of 364 MW / 280 MWh Solar + Storage Portfolio to Exus Renewables North America
- Artist Séfora Camazano Honored with Prestigious Prize "The New Great Masters in New York"
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.
Media Contact:
Julia Stern
(763) 350-5223
[email protected]
Investors:
Shveta Dighe
Head of Investor Relations
[email protected]
SOURCE Carisma Therapeutics Inc.
Filed Under: Business
0 Comments
Latest on The PennZone
- Children's Hospital of Philadelphia Researchers Find Gene Therapy Shows Long-Term Benefits for Hemophilia B Patients
- Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
- Thrive Cannabis Marketplace Opens New Main Street Dispensary in Las Vegas Arts District
- ReferFriends.io Officially Launches: A New Global Hub for Sharing and Discovering Referral Codes
- Emerging Managers Podcast Launches, Highlighting New Players in Venture Capital Outperforming the Status Quo
- North American Security Launches New Website to Reflect Evolving Industry Demands and Client-Centered Solutions
- Home Run Pest & Termite Control Launches Monthly Mosquito Service to Help Wylie, Plano, and Rockwall Homeowners Reclaim Their Backyards
- Jayson Warner Smith joins the cast of Tulsa King, The Good Daughter and Murdaugh Murders in 2025
- The Retirement Reality Check ABCs of Senior Housing Webinar Featuring Financial Expert Ty McGilberry
- Digital Watchdog and Deep Sentinel Partner to Deliver Integrated AI-Powered Security Solutions
- Local Leap Marketing Wins Creative Excellence Award for Healthcare Web Design
- Home Run Pest & Termite Control Delivers No-Contract Pest Solutions to Wylie, Rockwall & Surrounding Areas
- Lauren Coyle Rosen Unveils Debut Album 'Purify Flame'
- The Manifesto - Local Philadelphia - Live and Loud
- Peak Homebuying Season Begins: Realtor® Association Offers Tips to Be Well-Prepared for Successful Home Purchase
- American Mensa Welcomes 7-Year-Old Savannah Boy
- Portland Hosts Mensa's 2025 Mind Games®
- T&S and US Conec Ink Global Licensing Deal on MDC Technology to Advance High-Density Optical Interconnects
- Goosechase Rolls Out Unlockable Missions, Its Most Anticipated Feature Yet
- Couples Too Broke to Break Up – Divorce Expert Warns of Hidden Separation Crisis Amid Cost of Living Squeeze